Journal Wrap | HELIOS-B: Vutrisiran Lowers CV Events, Death Risk; Micro-Nanoplastic Accumulation and CV Health; More
The hottest research from various peer-reviewed journals – handpicked weekly by the ACC.org Editorial Board led by Kim A. Eagle, MD, MACC.
HELIOS-B: Vutrisiran Lowers Risk of CV Events, Death in ATTR-CM
In patients with ATTR-CM, vutrisiran, compared with placebo, was associated with a lower risk of cardiovascular events and all-cause death, according to findings from the HELIOS-B trial presented at ESC Congress 2024 and simultaneously published in the New England Journal of Medicine.
Micro-Nanoplastic Accumulation May Adversely Affect CV Health
The accumulation of micro-nanoplastics (MNPs) in the body may lead to adverse cardiovascular effects and may represent a novel risk factor for cardiovascular disease, according to a state-of-the-art review published in the European Heart Journal.
SAHELI: Does a Culturally Adapted Lifestyle Intervention Improve CVD Risk Factors?
A culturally adapted group-based lifestyle intervention targeted towards South Asian participants did not lead to a substantial difference in improving risk factors at one year compared with written health education materials, according to the single-blind randomized SAHELI study published in JAMA Cardiology.
Clinical Topics: Cardiovascular Care Team, Vascular Medicine
Keywords: Cardiology Magazine, ACC Publications, Standard of Care, RNA Interference, Microplastics, Hyperemia, Risk Factors, Inflammation, Life Style, Health Education, Prediabetic State
